Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression
Authors:
Open Access
- 6 July 2022
- journal article
- research article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 15 (1) , 1-24
Abstract
Background: Metastasis and chemoresistance are major culprits of cancer mortality, but factors contributing to these processes are incompletely understood. Methods: Bioinformatics methods were used to identify the relations of Smyca expression to clinicopathological features of human cancers. RNA-sequencing analysis was used to reveal Smyca-regulated transcriptome. RNA pull-down and RNA immunoprecipitation were used to examine the binding of Smyca to Smad3/4 and c-Myc/Max. Chromatin immunoprecipitation and chromatin isolation by RNA purification were used to determine the binding of transcription factors and Smyca to various gene loci, respectively. Real-time RT-PCR and luciferase assay were used to examine gene expression levels and promoter activities, respectively. Xenograft mouse models were performed to evaluate the effects of Smyca on metastasis and chemoresistance. Nanoparticle-assisted gapmer antisense oligonucleotides delivery was used to target Smyca in vivo. Results: We identify lncRNA Smyca for its association with poor prognosis of many cancer types. Smyca potentiates metabolic reprogramming, migration, invasion, cancer stemness, metastasis and chemoresistance. Mechanistically, Smyca enhances TGF-β/Smad signaling by acting as a scaffold for promoting Smad3/Smad4 association and further serves as a Smad target to amplify/prolong TGF-β signaling. Additionally, Smyca potentiates c-Myc-mediated transcription by enhancing the recruitment of c-Myc/Max complex to a set of target promoters and c-Myc binding to TRRAP. Through potentiating TGF-β and c-Myc pathways, Smyca synergizes the Warburg effect elicited by both pathways but evades the anti-proliferative effect of TGF-β. Targeting Smyca prevents metastasis and overcomes chemoresistance. Conclusions: This study uncovers a lncRNA that coordinates tumor-relevant pathways to orchestra a pro-tumor program and establishes the clinical values of Smyca in cancer prognosis and therapy.Keywords
This publication has 61 references indexed in Scilit:
- The hallmarks of cancerRNA Biology, 2012
- Genomic Maps of Long Noncoding RNA Occupancy Reveal Principles of RNA-Chromatin InteractionsMolecular Cell, 2011
- Novel Cationic Lipid That Delivers siRNA and Enhances Therapeutic Effect in Lung Cancer CellsMolecular Pharmaceutics, 2009
- Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progressionJournal of Clinical Investigation, 2008
- Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapyBreast Cancer Research, 2008
- Transforming growth factor-β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancerHepatology, 2008
- Dual roles of myocardin-related transcription factors in epithelial–mesenchymal transition via slug induction and actin remodelingJournal of Cell Biology, 2007
- Differential Regulation of Epithelial and Mesenchymal Markers by δEF1 Proteins in Epithelial–Mesenchymal Transition Induced by TGF-βMolecular Biology of the Cell, 2007
- TGFβ3 inhibits E-cadherin gene expression in palate medial-edge epithelial cells through a Smad2-Smad4-LEF1 transcription complexJournal of Cell Science, 2007
- Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damageNature, 2002